ArticleMedical hypotheses2024
Neuron-Targeted Exosome Therapy: A Novel Approach for Treating Cardiogenic Dementia via RyR2 Inhibition.
Article in Medical hypotheses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiogenic dementia (CD), recognized since the late 1970s, manifests as altered consciousness and cognition due to heart conditions. Its elusive molecular mechanisms present diagnostic and management challenges. Emerging research implicates ryanodine receptor type 2 (RyR2) mediated intracellular Ca2+ leaks in myocardial infarction (MI)-linked cognitive impairment. We hypotheses that intravenous delivery of neuron-targeted exosomes loaded with RyR2-targeting siRNA (si-RyR2) to cerebral regions could rectify Ca2+ imbalance, curbing neurotoxic protein generation tied to CD. To investigate, si-RyR2 exosomes will be administered to MI-induced mice, with hippocampal samples analyzed for Ca2+ levels, β-amyloid, and p-tau. Results hold promise for advancing CD treatment insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.